VBI Vaccines, Inc. (Nasdaq: VBIV) (TSX: VBV) (“VBI”), a commercial-stage biopharmaceutical company developing next-generation infectious disease and immuno-oncology vaccines, announced today that it has been added to the Russell 2000® and the Russell 3000® Indexes following the annual reconstitution, which took effect after the U.S. market closed on Friday, June 23.

“Inclusion in the Russell 2000® and 3000® Indexes is an important milestone for VBI that further validates the growing shareholder value we are building within VBI,” said Jeff Baxter, VBI’s President and CEO. “The Russell Indexes are closely followed by the investment community and we believe inclusion in these indexes will bring increased exposure and visibility for VBI.”The Russell 3000® Index measures the performance of the largest 3,000 U.S. companies, representing approximately 98% of the investable U.S. equity market. The Russell 2000® Index measures performance of the small-cap segment of the U.S. equity market and is a subset of the Russell 3000® Index, representing approximately 10% of the total market capitalization of the Russell 3000® Index. Membership in the Russell 2000® Index results in automatic inclusion in the appropriate growth and style indexes.

Russell Indexes are widely used by investment managers and institutional investors for index funds and as benchmarks for active investment strategies. Approximately $8.5 trillion in assets are benchmarked to or invested in products based on the Russell U.S. Indexes. Russell Indexes are provided by FTSE Russell, a leading global index provider. For more information, visit: https://www.ftserussell.com/research-insights/russell-reconstitution.